Advanced Mammography Systems has filed a 510(k) application with the Food and Drug Administrationfor Aurora, the company's dedicated MR mammography system. TheWilmington, MA, company, which is a majority-owned subsidiaryof fast MRI developer Advanced NMR
Advanced Mammography Systems has filed a 510(k) application with the Food and Drug Administrationfor Aurora, the company's dedicated MR mammography system. TheWilmington, MA, company, which is a majority-owned subsidiaryof fast MRI developer Advanced NMR Systems, unveiled Aurora atlast year's Radiological Society of North America meeting (SCAN11/23/94). The firm filed Aurora's 510(k) application in lateFebruary.
Aurora features a 0.5-tesla superconducting magnet that ishidden behind the rear wall of the examination room. The patientlies prone on the table and enters the magnet bore feet first.The patient's breasts are cupped without compression in built-inradio-frequency coils that are accessible from below for biopsy.List price of the system is expected to be $495,000.
Advanced Mammography Systems is in the final stages of negotiationswith several medical facilities for beta-site installations ofthe scanner, the company reported.
The company also reported that it has completed the redemptionof outstanding redeemable warrants for the purchase of the company'sstock. Advanced Mammography Systems said 773,935 warrant holdersout of a total 774,595 elected to purchase its stock at a priceof $3 a share. The transaction generated $2.3 million, which willbe used for R&D and working capital purposes.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.